Freund Yonathan, Gorlicki Judith, Cachanado Marine, Salhi Sarah, Lemaître Vanessa, Simon Tabassome, Mebazaa Alexandre
Sorbonne Université, Paris, France.
Emergency Department, Hôpital Pitié-Salpêtrière, Paris, France.
Trials. 2019 Jan 31;20(1):95. doi: 10.1186/s13063-019-3188-8.
Acute heart failure (AHF) is one of the most common diagnoses for elderly patients in the emergency department (ED), with an admission rate above 80% and 1-month mortality around 10%. The European guidelines for the management of AHF are based on moderate levels of evidence, due to the lack of randomized controlled trials and the scarce evidence of any clinical added value of a specific treatment to improve outcomes. Recent reports suggest that the very early administration of full recommended therapy may decrease mortality. However, several studies have highlighted that elderly patients often received suboptimal treatment. Our hypothesis is that an early care bundle that comprises early and comprehensive management of symptoms, along with prompt detection and treatment of precipitating factors should improve AHF outcome in elderly patients.
METHODS/DESIGN: ELISABETH is a stepped-wedge, cluster randomized controlled, clinical trial in 15 emergency departments in France recruiting all patients aged 75 years and older with a diagnosis of AHF. The tested intervention is a care bundle with a checklist that mandates detection and early treatment of AHF precipitating factors, early and intensive treatment of congestion with intravenously administered nitrate boluses, and application of other recommended treatment (low-dose diuretics, non-invasive ventilation when indicated, and preventive low-molecular-weight heparin). Each center is randomized to the order in which they will switch from a "control period" to an "intervention period." All centers begin the trials with the control period for 2 weeks, then after each 2-week step a new center will enter the intervention period. At the end of the trial, all clusters will receive the intervention regimen. The primary outcome is the number of days alive and out of the hospital at 30 days.
If our hypothesis is confirmed, this trial will strengthen the level of evidence of AHF guidelines and stress the importance of the associated early and comprehensive treatment of precipitating factors. This trial could be the first to report a reduction in short-term morbidity and mortality in elderly AHF patients.
ClinicalTrials.gov, ID: NCT03683212. Prospectively registered on 25 September 2018.
急性心力衰竭(AHF)是急诊科老年患者最常见的诊断之一,入院率超过80%,1个月死亡率约为10%。由于缺乏随机对照试验以及特定治疗改善预后的临床附加值证据稀缺,欧洲AHF管理指南基于中等水平的证据。近期报告表明,尽早给予完全推荐治疗可能降低死亡率。然而,多项研究强调老年患者常接受不充分治疗。我们的假设是,一个包含症状的早期和全面管理以及促发因素的及时检测与治疗的早期护理包应能改善老年AHF患者的预后。
方法/设计:ELISABETH是一项在法国15个急诊科进行的阶梯楔形、整群随机对照临床试验,招募所有年龄在75岁及以上且诊断为AHF的患者。所测试的干预措施是一个护理包,其中有一份清单,要求检测并早期治疗AHF促发因素,通过静脉注射硝酸酯类大剂量推注进行早期和强化的充血治疗,以及应用其他推荐治疗(低剂量利尿剂、必要时进行无创通气和预防性低分子量肝素)。每个中心被随机分配从“对照期”转换到“干预期”的顺序。所有中心均以2周的对照期开始试验,然后每2周有一个新的中心进入干预期。在试验结束时,所有群组都将接受干预方案。主要结局是30天时存活且未住院的天数。
如果我们的假设得到证实,这项试验将加强AHF指南的证据水平,并强调相关促发因素早期和全面治疗的重要性。这项试验可能首次报告老年AHF患者短期发病率和死亡率的降低。
ClinicalTrials.gov,标识符:NCT03683212。于2018年9月25日前瞻性注册。